Alice Gilman sat down for a podcast interview back in February. She spoke openly about her startup’s vision for growing structures packed with functioning organs yet stripped of any capacity for thought or feeling. Then months later she moved to stop it from airing.
The episode never went away. It dropped anyway. And the resulting fallout has pulled back the curtain on R3 Bio, a Richmond, California company that has spent years operating in the shadows before a burst of publicity earlier this year. What emerged was a pattern of bold claims followed by swift retreats. Public statements that appear to contradict private conversations. References to government ties that remain unexplained.
Gilman serves as cofounder and chief operating officer. In the Skyline Drive conversation with host Mangesh Hattikudur she described entities that contain “a heart, lungs, and everything that you would find in a body. But it’s not technically alive because it’s exclusively the organs.” She called them organ sacks. The term stuck. It captured both the clinical detachment of the concept and the visceral reaction it provokes.
Yet when producers contacted her in early July for a final fact check Gilman pushed back hard. She asked them to postpone the release. She stated that R3 Bio was not working on the idea “for now, period.” She described the company as a “federal asset” without offering details on what that phrase actually meant in this context. The podcast team found her response surprising. They published anyway on July 14.
Futurism broke the story the same day. Its account drew directly from the recorded interview and exchanges with the Skyline Drive producers. Maggie Harrison Dupré reported that Gilman had not disputed the accuracy of her earlier remarks. Instead she framed them as theoretical opinions rather than descriptions of active projects.
This reversal did not occur in isolation. R3 Bio first surfaced publicly in March through a Wired profile. The article detailed plans to create nonsentient monkey organ sacks as substitutes for live animal testing. Investor Boyang Wang told the magazine that “replacement is probably better than repair when it comes to treating diseases or regulating the aging process in the human body.” He added that a nonsentient headless bodyoid could serve as “a great source of organs.”
Wired also noted a job posting for a veterinarian in Puerto Rico skilled in implanting embryos and monitoring primate pregnancies. That detail gained extra weight after Gilman’s podcast comments. She told Hattikudur the company sought “monkey access” without confining animals in cages. The solution involved an island where monkeys roam freely. Researchers could approach them, collect skin cells, and avoid what she viewed as unethical housing practices. “I’m a big animal rights advocate,” she said. “I don’t want to keep monkeys in cages.”
R3 Bio’s own website tells a different story. It declares that the firm does not work with live primates. It further states there is “no ongoing work” in full-scale human organ fabrication and that the underlying science “is currently not ready.” The contrast between these disclaimers and the podcast remarks has fueled skepticism among observers.
Days after the Wired piece appeared MIT Technology Review published its own investigation. It examined cofounder John Schloendorn, a self-described biological designer. The outlet uncovered confidential talks in which he discussed “full body replacement” and “recent lab progress towards making replacement bodies.” Such terms point toward far more ambitious goals than organ testing platforms. They suggest the possibility of growing entire brainless humanoids that could one day accept head transplants or serve as sources for comprehensive tissue renewal.
R3 Bio responded to the MIT Technology Review story with what the publication called a “sweeping disavowal.” The company rejected any suggestion it intended to create human clones or beings with intentional brain damage. It insisted Schloendorn had made no such statements about nonsentient human clones carried by surrogates.
Yet the pattern repeats. Bold visions surface in controlled settings. Detailed technical discussions occur in interviews. Then corporate communications walk them back once wider attention arrives. Hattikudur later told Futurism he was surprised by the attempt to suppress the episode. “The company hasn’t been exactly transparent about what they’re doing,” he said. “There’s a lot of mix between the hype they’re telling people and what they’ve actually achieved in the lab, which is not very clear.”
The scientific hurdles remain substantial. Gilman herself acknowledged them during the February recording. She explained that reducing nervous system complexity to improve social acceptance also limits the organs’ ability to sustain themselves. “There are other constraints on the ability of the organs to preserve themselves,” she noted. Mouse models can survive with minimal neural infrastructure. Scaling that to larger, more complex systems introduces trade-offs that the company is still mapping.
Progress reports offer only partial clarity. In March R3 Bio released a 2026 research summary focused on stem cell-derived integrated systems aimed at replacing animal testing. The document, covered by Newsfile Corp and Yahoo Finance, described early-stage work on biological platforms reprogrammed from skin cells. It referenced Yamanaka factor techniques that earned Shinya Yamanaka a Nobel Prize. No mention appeared of primate involvement or full-body constructs.
Investors appear undeterred by the mixed signals. The Wired article listed backing from billionaire Tim Draper, the Singapore-based Immortal Dragons fund, and longevity-focused LongGame Ventures. Their participation signals confidence that the underlying stem cell biology could eventually deliver practical tools even if current demonstrations remain modest.
Bioethicists have watched developments with growing alarm. The prospect of creating entities that possess human-like organs but lack consciousness raises profound questions about moral status, consent, and the boundaries of laboratory creation. Gilman told Hattikudur she tries “to not be scary to an average person.” That effort has proven difficult. Public discussion quickly shifts from replacement organs to deeper concerns about what counts as life and who decides its value.
Regulatory gaps compound the uncertainty. Federal oversight of stem cell research is strict yet fragmented. Private companies can explore novel constructs in jurisdictions with lighter rules. Puerto Rico’s island monkey populations have long attracted biomedical interest precisely because of their accessibility and genetic proximity to humans. Gilman’s description of negotiating with local supervisors for non-caged access adds another layer to an already complex operational picture.
Schloendorn’s background adds further intrigue. His talks on full body replacement echo ideas once confined to speculative fiction. Scientists have debated head transplantation for years with limited success in animal models. Bringing such procedures into clinical reality would require not only biological scaffolds but also advances in neural interfacing, immunosuppression, and rehabilitation that remain distant. R3 Bio’s website carefully distances itself from those timelines while leaving the door open for future possibility.
The “federal asset” comment lingers unresolved. Gilman offered no elaboration. Government agencies sometimes partner with private firms on sensitive biotechnology through grants, contracts, or classified programs. Without confirmation the phrase functions more as an assertion of importance than a verifiable claim. Neither R3 Bio nor any federal department has commented publicly on potential connections.
Futurism attempted to reach the company with specific questions. Why seek to delay the podcast? Are plans underway to collect skin cells from free-roaming island monkeys and if so how? What precisely does “no ongoing work” mean when earlier interviews described active milestones? No response had arrived by publication.
The episode reveals tensions that define much of modern biotechnology. Companies race to demonstrate progress to secure funding and talent. They simultaneously shrink from scrutiny that could invite regulation or public backlash. Transparency becomes selective. Technical terms are deployed in investor meetings and then softened for broader consumption.
Hattikudur captured the frustration. “If they were honest that this is what they believe in, and this is what they’re working on, it would actually be less of a big deal. It’s more that they awkwardly seem to be hiding something which everyone kind of knows about.”
Whether R3 Bio ultimately delivers functional organ platforms or merely highlights the limits of current stem cell science remains to be seen. The conversation it has sparked will not fade quickly. Organ sacks. Bodyoids. Replacement chassis. The vocabulary alone forces society to confront choices about how far to extend laboratory control over biological forms that blur every traditional line between tool, organism, and person.
And the startup’s next move could prove just as revealing as its last. Continued silence might suggest internal debate over how much to disclose. Fresh announcements could test whether the disavowals hold or whether the original ambitions resurface under new framing. For an industry that sells the promise of extended life the ability to speak plainly about its methods may prove one of the hardest tests of all.
Silicon Valley’s Organ Sacks Mystery: Startup’s Podcast Reversal Sparks Fresh Questions on Biotech Ambitions first appeared on Web and IT News.